NCCN's Putnam Serving as Point of Contact for Payers, Employers to Keep Cancer Care "Accessible"

Evidence-Based OncologyJune 2019
Volume 25
Issue 6

A year ago, the National Comprehensive Cancer Network (NCCN) added the word “accessible” to its mission statement, stating that the group is “dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so that patients can live better lives.”

A year ago, the National Comprehensive Cancer Network (NCCN) added the word “accessible” to its mission statement, stating that the group is “dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so that patients can live better lives.”1

But innovative therapies won’t reach patients unless payers and, increasingly, employers are willing to include them in benefit plans. So, in March, NCCN named Duane Putnam, BBA, as its director of Payer and Employer Outreach, giving these stakeholders their own point of contact.

Putnam has spent more than 30 years working at the intersection of pharmaceuticals and reimbursement, having spent much of his career at Pfizer as a director of employer relations. During that time, he has seen NCCN’s clinical practice guidelines become the focal point for payers in making coverage decisions.2,3 As employers take a more active role in benefit design, it will be Putnam’s job to educate employers about NCCN’s guideline development process.

Evidence-Based Oncology™ (EBO) spoke with Putnam about his new role and the challenges ahead.


Why is it important for NCCN to have a designate point of contact for payers and employers? PUTNAM: In 2018, NCCN added the word “accessible” to its mission statement to read, “NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives.” Most of those patients are somebody’s employee or the dependent of an employee, or members of a payer. So, what we want to do is keep that mission top of mind for the payers and employers, because they have so much influence on access.

What I can do is make it more convenient for them to have one point of contact here at NCCN. It helps me to learn their priorities related to cancer care, and it helps me see where their priorities overlap with each other and where they do not.


NCCN guidelines have become the gold standard for payers who are making coverage decisions. Have payers learned about your appointment, and if so, what kind of feedback have you received? PUTNAM: The NCCN Guidelines and derivatives are utilized by CMS and private payers for coverage policy for approximately 85% of covered lives in the United States. As for employers, and their knowledge of NCCN, there’s still room for improvement, but I’m pleased at the initial uptake. That’s part of my goal in the weeks to come—to take the initiative and to build a bridge to work together.


How do you envision these relationships informing guideline development? PUTNAM: These relationships will not inform guideline development, as the development of the NCCN Guidelines is protected by a very strict firewall. The firewall surrounding those processes includes financial support policies, panel participation policies, communication policies, disclosure policies, and policies regarding relationships to NCCN business development. Payers and employers, like any stakeholder, are welcome to submit data for consideration by the NCCN Guidelines Panels via This process and our full firewall policy can both be found on


We are hearing more and more about employers—not just large employers but also midmarket employers—taking a more active role in benefit design and wellness to hold down healthcare costs. Much of your career has been spent engaging employers. How have you seen the role of the employer evolve, and how do you see it evolving in this era of transformative, but expensive, cancer therapies? PUTNAM: Purchasers, employers, and payers may look at this as a cost center. Fortunately, over the last decade or so, employers have become more educated consumers; they are no longer willing just to hire outside help and rely on them exclusively to do what needs to be done. They are asking good questions.

What’s interesting is that the employers are actually a collection of consumers. So, employers are consumers, but they have employees who are consumers, and once again, NCCN is able to help both groups through the NCCN Guidelines and NCCN Guidelines for Patients. You need a surround sound approach for the employers and the employees when they are in with their treatment team, every doctor will say, “The better educated the patient is, the easier my job is.” We would like to share the materials we have and help the employer.

It’s hard to ignore the cost of care, but if you put that in perspective and look at the lost productivity and the cost of replacement workers, the costs for absence, short-term disability, and long-term disability, the direct costs become a smaller piece of the pie. Hopefully, we will help employers look at evidence-based care as an investment to maximize rather than a cost to try to minimize.


: At the most recent conference, major emphasis was placed on the need to expand genomic testing across cancer states. How are payers doing in reimbursement for testing? PUTNAM: There’s an opportunity there…if [the tests] are proven and evidence-based, they can actually reduce cost and reduce waste because they can help the clinician select effective and efficient treatments. The NCCN Biomarkers Compendium, based directly on the NCCN Guidelines, supports clinical decision-making related to the use of drugs and biologics, biomarker testing, imaging, and radiation therapy for people with cancer. The goal of the NCCN Biomarkers Compendium is to provide essential details for those tests, which have been approved by NCCN Guidelines Panels and are recommended by the NCCN Guidelines. The tests that measure the changes in the genes, the gene products, which can be used for diagnosis, for screening and monitoring, surveillance, providing predictive and prognostic information—they are all included in there. We are hoping that the NCCN Biomarkers Compendium is used by payers, much the same way the drugs and biologics compendium is now utilized as a reference for coverage decisions. The challenge is how to wade through the different tests that are coming out to make good decisions and to make sure they are evidence-based and can stand up to scrutiny.


What other major challenges do you foresee over the next 1 to 2 years with payers and employers? PUTNAM: Payers are aware of the NCCN Guidelines. The employers, maybe not so much, which is understandable. We need to let them know what NCCN is about and what we do, as well as the fact that NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. I want them to understand how diligent we are in that mission.

As stated earlier, NCCN has strict policies to shield the guideline development process from external influences. And I think that’s maybe where the employers are less informed. If anybody is concerned that someone is influencing the people who are advising [the guidelines panels], so that it becomes self-serving for those third parties, that’s great for me, because I can look anybody in the eye and say, “It’s not the case with NCCN.”

A second challenge would be understanding how to best help employers and payers utilize the NCCN Guideline to support a robust continuum of care design that is evidence-based. The goal should be not how much to spend, but how well. REFERENCES:

  1. About NCCN [National Comprehensive Cancer Network]. NCCN website. Accessed May 10, 2019.
  2. McGivney WT. The National Comprehensive Cancer Network: present and future directions. Cancer. 1998;82(10 suppl):2057-2060.
  3. McGivney WT. NCCN guidelines and their impact on coverage policy. J Natl Compr Canc Netw. 2010;8(6):625.
Related Videos
Screenshot of Sancy Leachman, MD, PhD, smiling
Screenshot of Sancy Leachman, MD, PhD
Sashi Naidu, MD, Carolina Blood and Cancer Care Associates
Dr. Lalan Wilfong
Dr. Ryan Huey
David A. Eagle, MD, New York Cancer & Blood Specialists
Screenshot of Sancy Leachman, MD, PhD, smiling
Manmeet Ahluwalia, MD, MBA.
Nicolas Ferreyros, BA, managing director, The Community Oncology Alliance
Susan Sabo-Wagner, MSN, RN, OCN, Oncology Consultants
Related Content
© 2023 MJH Life Sciences
All rights reserved.